Leap Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview

Cypherpunk Technologies

08/11/2024 17:01

* Leap Therapeutics Inc  LPTX.OQ   LPTX.O  is expected
to show no
change in quarterly revenue when it reports  results on November
11 (estimated) for the period ending September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Leap Therapeutics Inc is
for a
loss of 48 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Leap
Therapeutics
Inc is 12.00​, above​ its last closing price of $3.47. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.44       -0.43      -0.52     Missed  -20.9
 Jan. 1 2024   -0.58       -0.58      -0.51     Beat    12.8
 Jan. 1 0001               -0.55      -0.46     Beat    16.4​
 Sep. 30 2023  -0.57       -0.58      -0.51     Beat    11.8
 ​​Jun.        -0.90       -0.90      -0.91     Missed  -1.6
 30 2023                                                
 Jan. 1 0001   -1.00       -0.98      -3.20     Missed  -226.5
                                                        ​
 Dec. 31 2022              -1.10      -1.00     Beat    9.1
 Sep. 30 2022  -1.25       -1.20      -1.30     Missed  -8.3
 This summary was machine generated November 8 at 17:01 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)